Neprilysin activity is increased in metabolic dysfunction-associated steatotic liver disease and normalizes after bariatric surgery or GLP-1 therapy

Summary: Inhibitors of neprilysin improve glycemia in patients with heart failure and type 2 diabetes (T2D). The effect of weight loss by diet, surgery, or pharmacotherapy on neprilysin activity (NEPa) is unknown. We investigated circulating NEPa and neprilysin protein concentrations in obesity, T2D...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Sasha A.S. Kjeldsen, Lise L. Gluud, Mikkel P. Werge, Julie S. Pedersen, Flemming Bendtsen, Kleopatra Alexiadou, Tricia Tan, Signe S. Torekov, Eva W. Iepsen, Nicole J. Jensen, Michael M. Richter, Jens P. Goetze, Jørgen Rungby, Bolette Hartmann, Jens J. Holst, Birgitte Holst, Joachim Holt, Finn Gustafsson, Sten Madsbad, Maria S. Svane, Kirstine N. Bojsen-Møller, Nicolai J. Wewer Albrechtsen
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Elsevier 2023-11-01
Schriftenreihe:	iScience
Schlagworte:	Health sciences Obesity medicine Diabetology
Online-Zugang:	http://www.sciencedirect.com/science/article/pii/S2589004223022678
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!